Derniers articles

Metastatic renal cell carcinoma: Management of toxicities of combinations

AbstractNew combinations of antiangiogenic tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) or...

Posté par :
Nom de la revue : Bulletin du cancer

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...

Posté par :
Nom de la revue : Bulletin du cancer

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

AbstractUntil recently, the first-line treatments used in metastatic renal cell carcinoma were based on first-generation...

Posté par :
Nom de la revue : Bulletin du cancer

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review

AbstractAim: A systematic literature review of immuno-oncology trials was conducted to assess the potential impact of...

Posté par : Mr. Antoine FALCOZ,
Nom de la revue : Qual Life Res

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...

Posté par : Dr. Dewi VERNEREY, , Dr. Angélique VIENOT
Nom de la revue : Front Oncol

Feasibility of health‑related quality of life (HRQoL) assessment for cancer patients using electronic patient‑reported outcome (ePRO) in daily clinical practice

AbstractIntroduction - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical...

Posté par : , Mr. Antoine FALCOZ, Mme. Joëlle FRITZSCH, , , Dr. Sophie PAGET-BAILLY
Nom de la revue : Quality of Life Research

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials

AbstractBackground: While open-label randomized controlled trials (RCT) are common in oncology, some concerns have...

Posté par :
Nom de la revue : Cancer Med

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

AbstractBackground Metastatic Squamous cell Penile Carcinoma (mSCPC) is an orphan disease with a virally induced...

Posté par : , Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Nom de la revue : Bull Cancer

26 May, 2020

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review

AbstractBackground: Patients with severe renal impairment or undergoing hemodialysis are usually excluded from...

Posté par :
Nom de la revue : Semin Oncol

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

ABSTRACTBACKGROUND:Two main therapies, pazopanib and sunitinib, are used in the first-line settingfor metastatic renal...

Posté par : , Mme. Joëlle FRITZSCH, Dr. Sophie PAGET-BAILLY, , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : Health and Quality of Life Outcomes

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

ABSTRACTDespite the importance of metastatic clear-cell renal cell carcinoma, studies on its economic burden in daily...

Posté par : ,
Nom de la revue : Clinical Genitourinary Cancer

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

AbstractBackgroundNivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for...

Posté par : ,
Nom de la revue : European Journal of Cancer

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

ABSTRACTBackgroundSunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma...

Posté par : , Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Nom de la revue : Trials

Évaluation de la qualité de vie relative à la santé suite au diagnostic de cancer

La mesure de la qualité de vie relative à la santé des personnes traitées pour un cancer se développe. Ce nouvel...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Mme. Joëlle FRITZSCH,
Nom de la revue : La revue de l'infirmière

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Background: Deficient mismatch repair (dMMR) colon cancer (CC) is reportedly resistant to 5-fluorouracil (5FU) adjuvant...

Posté par : , Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : JNCI Journal of the National Cancer Institure

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

BACKGROUND:A randomized multicenter phase II trial was conducted to assess the sequential treatment strategy using...

Posté par : Pr. Franck BONNETAIN, , Dr. Sophie PAGET-BAILLY
Nom de la revue : PlosOne

Derniers articles

Metastatic renal cell carcinoma: Management of toxicities of combinations

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life)

Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma

Feasibility of health‑related quality of life (HRQoL) assessment for cancer patients using electronic patient‑reported outcome (ePRO) in daily clinical practice

Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials

Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE

Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Évaluation de la qualité de vie relative à la santé suite au diagnostic de cancer

Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.

 Archives

 Contributor

↑